BRAF G466A
|
NSCLC
|
BRAF G466A
|
NSCLC
|
LXH254 + LTT462 Sensitive: C3 – Early Trials
|
LXH254 + LTT462 Sensitive: C3 – Early Trials
|
BRAF G466A
|
CRC
|
BRAF G466A
|
CRC
|
cetuximab Resistant: D – Preclinical
|
cetuximab Resistant: D – Preclinical
|